Business
Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort
The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nThe Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common in never smokers – that lead to tyrosine kinase inhibitor (TKI) treatment resistance, and to enhance patient outcomes when LP-300 is used with the standard-of-care chemotherapy doublet.\n\n\n\nIn the Phase 2 lead-in cohort of 7 patients, 6 patients experienced clinical benefit from the combination of LP-300 and chemotherapy while 1 patient experienced progressive disease.\n\n\n\nOf the 6 patients experiencing clinical benefit – 3 patients showed partial responses with an average tumor size reduction of 51% and 3 patients have stable disease with an average tumor size reduction of 13%.\n\n\n\nThe clinical benefit rate and disease control rate is 86% for this group with an objective response rate (ORR) of 43%.\n\n\n\nA preliminary analysis of data in the safety lead-in part of the trial indicates no additional safety concerns with no observed dose limiting toxicities (DLTs) and no reported treatment-related serious adverse events (SAEs).\n\n\n\nEncouraging preliminary efficacy results were observed regardless of prior tyrosine kinase inhibitor (TKI) treatment(s), demographics, and metastatic disease sites.\n\n\n\nIn the initial set of patients, those having low to intermediate TMB (tumor mutation burden) were found to be responsive to LP-300 + chemotherapy.\n\n\n\nThere are no currently approved therapies or targeted agents specifically approved for use in NSCLC among never-smokers, which is a growing global class of patients.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development, today announced positive, preliminary results from the initial patient group in the ongoing HARMONIC™ phase 2 clinical trial. HARMONIC™ is evaluating Lantern Pharma’s investigational new drug candidate, LP-300, in combination with pemetrexed and carboplatin in never smokers1 with advanced non-small cell lung cancer (NSCLC) who have progressed after receiving treatment with a tyrosine kinase inhibitor (TKI). LP-300 was advanced in part with Lantern’s AI platform, RADR®, to aid in the validation of mechanisms and uncove...